Navigation Links
Kiadis Pharma Announces Collaboration With the Julius Maximilians University of Wurzburg, Germany
Date:5/29/2008

Dr. Mielke Continues his Collaboration With Kiadis Pharma on ATIR(TM)

AMSTERDAM, May 29 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announces today the clinical development collaboration for its lead product ATIR(TM) with Dr. Stephan Mielke and Professor Dr. Hermann Einsele from the Allogeneic Stem Cell Transplant Center, Division of Hematology and Oncology, Department of Internal Medicine II at the Julius-Maximilians University of Wurzburg, Germany. Principal investigator of this collaboration will be Dr. Mielke.

Previously, Dr. Mielke initiated the ongoing phase II clinical study for ATIR(TM) as principal investigator at the Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in Bethesda, Maryland, USA, together with Dr. John Barrett, Chief of the Allogeneic Stem Cell Transplant Section at the Hematology Branch. The investigators selected ATIR(TM) for a clinical study after a pre-clinical research program and have published the pre-clinical data showing promising results with Kiadis Pharma's ATIR(TM) in eliminating alloreactive T-cells from donor grafts (Mielke et al. Blood 2008). Dr. Mielke and colleagues additionally developed a reliable large scale manufacturing protocol with a "GMP-like" semi-closed system for cell processing with ATIR(TM).

"We are extremely pleased with this collaboration which shows the interest of leading transplantation physicians to continue working with our lead product ATIR(TM) as well as to participate in setting up our next clinical study in Europe," says Dr. Manja Bouman, CEO of Kiadis Pharma.

According to Dr. Mielke selective allodepletion with ATIR(TM) carries significant potential for improving the outcome of mismatched (haploidentical ) transplants by allowing early immune reconstitution with less severe or no acute Graft versus Host Disease (GvHD). Therefore, Dr. Mielke and his team and Kiadis Pharma are planning to initiate a clinical phase III study for mismatched (haploidentical) transplantations in blood cancer patients at the Julius-Maximilians University of Wurzburg.

About ATIR(TM)

ATIR(TM) is designed to prevent life-threatening acute GvHD by eliminating the immune cells from the donor graft that otherwise attack the patient's body. Useful donor immune cells that can fight infections and remaining tumor cells are, however, spared, allowing rapid and safe donor immune reconstitution post transplantation. Acute GvHD is a major complication of allogeneic bone marrow transplantations. By preventing the occurrence of acute GvHD, ATIR(TM) enables the use of a mismatched donor and consequently addresses a significant limitation in bone marrow transplantations, which is the timely availability of a donor. Moreover, it could improve the general outcome of bone marrow transplants.

About Kiadis Pharma

Kiadis Pharma is an oncology company focused specifically on complications and limitations of bone marrow transplantations in blood cancer patients. The company has three products in clinical development that offer novel treatment options for terminally ill blood cancer patients and address high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands with facilities in Groningen, The Netherlands and Montreal, Canada. For more information about Kiadis Pharma, please visit http://www.kiadis.com.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Kiadis Pharma Announces Promising Phase II Clinical Trial Results for Reviroc
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
(Date:6/23/2016)... DIEGO , June 23, 2016 ... programs that address medical conditions resulting from a ... it has appointed Greg Doyle as ... of Leading BioSciences, executive management team and board ... and chief financial officer. He will provide continued ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):